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Nitric oxideMiltefosine is an anticancer drug currently used to treat visceral and cutaneous leishmaniasis, also presents a
broad-spectrum of fungicidal and antiamoebae activities. It acts on the metabolism of phospholipids and glyco-
proteins of themembrane of parasites. Our study aimed to evaluate the effects of miltefosine (0.4 to 50.0 μg/mL)
on the phagocytosis and nitric oxide production by macrophages of C57BL/6 mice to clarify the immunomodu-
latory effects of the drug onmacrophages of C57BL/6, strainmice that is biased to Th1 response. Peritoneal mac-
rophages were in vitro treated with miltefosine and phagocytosis of sensitized or nonsensitized Saccharomyces
cerevisiae was assessed. NO production was evaluated by Griess reaction. In the concentration of 1.6 μg/mL
and 50.0 μg/mL, miltefosine increased phagocytosis of non-opsonized S. cerevisiae in 59.7% and 214.3%, respec-
tively. For phagocytosis through opsonin receptors, miltefosine (50.0 μg/mL) increased the phagocytic index in
208.6% (p=0.04, paired t test). Miltefosine (50.0 μg/mL) decreased in 39.3% NO production by macrophages.
However, treatment with miltefosine (50.0 μg/mL) after infection of macrophages with Leishmania amazonensis
increased NO production in 73.4% (p=0.01, Wilcoxon test). Our data showed that, besides the antimicrobial ef-
fect of miltefosine, the drug showed immunomodulatory effects on macrophages of C57BL/6 mice, improving
phagocytosis and decreasing NO production, but was able to increase NO production when macrophages were
previously infected with L. amazonensis. These results suggest that miltefosine may favor the better evolution
of infectious diseases by improving the innate immune response of macrophages.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Miltefosine (hexadecylphosphocholine) was originally developed
as an anticancer drug. This drug was shown to be effective against
promastigote and amastigote forms of Leishmania and is currently
used as an alternative drug, with lower toxicity than antimonials, for
treatment of visceral and cutaneous leishmaniasis [1–6]. Miltefosine
also presents a broad-spectrum of fungicidal [7–10] and antiamoebae
activities [11,12].
It has been suggested that the efﬁcacy of miltefosine against a
broad-spectrum of microorganisms is possibly related to its direct
toxicity, because the drug alters the cell membrane composition, in-
terferes in the metabolism of phospholipids and in the biosynthesis
of glycoproteins [13–15]. Miltefosine also activates the apoptosis
pathway in microorganisms [16,17] and acts on promastigotes ofand CNPq (478575/2008-4).
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evier OA license.Leishmania inducing a large increase in intracellular Ca2+ levels,
probably through the activation of plasma membrane Ca2+ channel
[18]. Thus, miltefosine is thought to act directly by targeting important
biological features of the parasite [18]. However, miltefosine is consid-
ered to possess potent immunomodulatory properties and its inﬂuence
on cells of innate immune system involved in defense against Leishmania
still remains incompletely understood [19,20].
Hilgard and colleagues assessed phagocytosis by macrophages
obtained from the bone marrow of BALB/c mice that showed natural
susceptibility to Leishmania infection. They showed a dose-dependent
inhibition of phagocytosis by treatment with low concentration of
miltefosine (0.1–10 μg/mL) [19]. But the inﬂuence on phagocytosis
of the therapeutic concentration of the drug is not known. Further-
more, the inﬂuence of miltefosine on phagocytosis by macrophages
of resistant strain of mice to Leishmania infection is unknown.
The anti-leishmanial oxidant nitric oxide produced by phagocytes
is generated after macrophage activation by interferon-γ and tumor
necrosis factor-α and this is the most relevant molecule to restrain
established intracellular amastigotes [21]. The speciﬁc release of
nitric oxide by peritoneal macrophage was induced only by the
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sequent stimulation by LPS in vitro, and started after 12 h of in vitro
incubation of macrophages with the endotoxin [22]. However, nitric
oxide production by dentritic cells was unaltered upon miltefosine
treatment [15]. The inﬂuence of miltefosine on nitric oxide produc-
tion is until now controversial.
It has been suggested that the susceptibility of BALB/c mice to
Leishmania infection occurs by its bias to a Th2 immune response
[23,24], and treatment with miltefosine was able to reverse to a Th1
response, the biased Th2 response of Leishmania donovani-infected
macrophages [25].
The natural resistance of C57BL/6mice to Leishmania infection is due
to its Th1 immune pattern of response [24]. Treatment of Leishmania-
infected-macrophages from C57BL/6 mice with miltefosine did not
alter the production of TNF-α, IL-12 p40, IL-12p70 and IL-10, but this
drug reestablished the production of nitric oxide when co-incubated
with IFN-γ and TNF-α [15].
It has been reported that miltefosine may affect the innate immune
response of monocytes/macrophages. As these cells are the main cells
involved in the control of infectious diseases, it is necessary to clarify
if the drug affects the mechanisms of defense of these cells. Among
the functions of macrophages that can be affected by miltefosine, the
phagocytosis deserves a highlight, because it depends on the ﬂuidity
of the cell membrane and expression of receptors, which can be altered
by drugs that interfere in the lipoprotein molecules, as miltefosine does
[26]. Furthermore, macrophages in vitro incubated with miltefosine in-
creased nitric oxide and TNF production by cells obtained from BALB/c
mice [22]. However, in Leishmania-infected-macrophages of C57BL/6
mice, this drug did not alter the production of the cytokines TNF-α,
IL-12 p40, IL-12p70 involved in nitric oxide production [15].
Considering that miltefosine can interfere with the main innate
immune defense mechanisms, this study aimed to evaluate the effects
ofmiltefosine onphagocytosis and nitric oxide productionbyperitoneal
macrophages, in order to elucidate the immunomodulatory effects of
the drug in the C57BL/6 mice.
2. Materials and methods
2.1. Animals and ethic aspects
The Animal Research Ethical Committee of the University of Brasi-
lia approved the experimental protocol of this work (process number
11254/2010). This study was exclusively designed and conducted by
the authors, who have no conﬂict of interest.
Phagocytosis of Saccharomyces cerevisiae by peritonealmacrophages
was assessed in presence or absence of opsonins. Nitric oxide produc-
tion by peritoneal macrophages was assessed with the phagocyte in
vitro infected or not with Leishmania amazonensis. Peritoneal macro-
phages were obtained from C57BL/6 femalemice (n=10), 2–4 months
old, and phagocytosis and nitric oxide production were assessed as de-
scribed below. The maximum concentration of miltefosine (hexade-
cylphosphocholine, Zentaris, GmbH, Germany) used in this study
(50 ng/mL) was based on the maximum plasma concentration
reported in the pharmacokinetic study of Dorlo et al. [27].
2.2. Leishmania amazonensis isolate
The isolate IFLA/BR/67/pH8 of L. amazonensiswas obtained from the
Laboratory of Dermatology, Faculty ofMedicine, University of Brasilia. It
was kept cryopreserved in liquid nitrogen until transferred to NNN-LIT
medium and cultured at 22 °C for 48 h. A small aliquot was added to
Schneider insectmedium (Sigma-Aldrich, St. Louis, USA), supplemented
with 20% heat-inactivated fetal calf serum and gentamicin sulfate
(40 mg/mL) (Schering Plough, São Paulo, Brazil), and cultured until the
log phase was reached.2.3. Test of phagocytosis by macrophages
The effect of miltefosine on phagocytosis of S. cerevisiae by perito-
neal macrophages was evaluated by incubating mouse macrophages
in the presence or not of miltefosine. Peritoneal cells were obtained
by washing the peritoneal cavity with 10 mL of cold PBS, pH 7.2. Re-
covered macrophages were washed with cold PBS (400×g, 10 min),
quantiﬁed in hemocytometer and suspended into cold RPMI 1640
medium (Sigma, St Louis, MO, USA), pH 7.2, supplemented with
20 mM Hepes (Sigma), 2 mM glutamine (Sigma) and 2.5 mg/dL gen-
tamicin. Viability was assessed with 0.05% nigrosin solution in 0.15 M
PBS, pH 7.2, and was always higher than 97%. Samples of 2×105 macro-
phages in RPMI 1640 were placed on 13 mm-diameter glass coverlips in
24-well plastic plates, incubated for 2 h in awet chamber, at 37 °C, in the
presence of 5% CO2 in air. The coverslips were then rinsed with PBS, and
adherent cells (>98% macrophages, average 16.84±1.64 cells/cover-
slip) were incubated for 30 min with 4×106 S. cerevisiae yeast per well,
prepared according to Muniz-Junqueira [28], and with miltefosine in
the following concentrations 0, 0.4, 1.6, 3.2, 12.5, 25 or 50 μg/mL, sus-
pended in 500 μL of RPMI 1640, supplemented with 10% inactivated
fetal calf serum (Invitrogen, Carlsbad, CA, USA).
Prior to addition to well prepared with adherent cells, killed S.
cerevisiae were either pre-sensitized by incubating yeasts for
30 min at 37 °C in RPMI solution containing a pool of 10% mouse
fresh sera (“sensitized”), or pre-incubated for 30 min at 37 °C with
RPMI solution containing 10% heat-inactivated fetal calf serum (“non-
sensitized”). Pre-sensitized yeast cells are phagocytosed mainly through
complement receptorswhile non-sensitized yeast cells are phagocytosed
through pathogen-associated molecular pattern receptors [29].
Preparations were then rinsed with PBS at 37 °C to eliminate non-
phagocytosed S. cerevisiae yeast cells, ﬁxed with absolute methanol,
stained with 10% buffered Giemsa solution, pH 7.2, and the number of
yeast cells bound to or ingested by macrophages in individual prepara-
tions was assessed by microscopy. Microscopic ﬁelds distributed
throughout the coverslips were randomly selected and all macrophages
in each ﬁeld were examined. The phagocytic index was calculated as the
average number of ingested yeasts per phagocytosing macrophage mul-
tiplied by the percentage of these cells engaged in phagocytosis [29].
2.4. Nitrite production
The nitrite (NO2−) production by 2×105 peritoneal macrophages
was evaluated with macrophages infected or not with L. amazonensis.
To non-infected macrophages, adhered cells were incubated in the
presence or not of miltefosine (0.0, 0.4, 1.6, 3.2, 12.5, 25 or 50 μg/
mL) for 24 h. To infected macrophages, adhered macrophages were
previously incubated with 106 promastigotes for 7 h, the cells were
then rinsed with PBS to remove non ingested L. amazonensis and,
after that, they were incubated with miltefosine (0.0, 0.4, 1.6, 3.2,
12.5, 25 or 50 μg/mL) for 24 h.
The assay was performed in triplicate in a wet chamber, at 37 °C
with 5% CO2 in air, in 96-well ﬂat-bottommicroplates. Macrophages in-
cubated with 10 μg/mL lipopolysaccharide from Escherichia coli sero-
type 055:B5 (Sigma, St Louis, MO, USA) were used as positive control.
After 24 h incubation, supernatants (100 μL) were incubated with
equal volume of Griess reagent (1% sulphanilamide/0.1% N-1-
naphthylethylene diamine dihydrochloride/2.5% H3PO4) at room
temperature for 10 min, and absorbance was assessed in the Spectra-
Max® Plus384 microplate (Molecular Device, Sunnyvale, USA) at
540 nm. The results were expressed as μM NO2− [30].
2.5. Statistical analysis
The data were tested employing Bartlett's test for equal variances
and the Kolmogorov–Smirnov test for the normality of their distribu-
tion before comparative analysis. To compare two pair-wised samples,
Fig. 2. Inﬂuence of miltefosine on phagocytosis of sensitized S. cerevisiae by peritoneal
macrophages of C57BL/6 mice (n=10). Macrophages (2×105) were incubated with
106 S. cerevisiae per well, in the presence or absence of miltefosine (0.0, 0.4, 1.6, 3.2,
12.5, 25.0 or 50.0 μg/mL). Data are expressed as median, quartiles and extreme values.
Bottom: Phagocytic index. Middle: Proportion of macrophages engaged in phagocyto-
sis. Top: Average number of S. cerevisiae ingested by macrophage. In all panels the
groups treated with 50.0 μg/mL of miltefosine were signiﬁcantly higher than that of
untreated cells (paired t test).
Fig. 1. Inﬂuence of miltefosine on phagocytosis of non-sensitized S. cerevisiae by peri-
toneal macrophages of C57BL/6 mice (n=10). Macrophages (2×105) were incubated
with 106 S. cerevisiae per well, in the presence or absence of miltefosine (0.0, 0.4, 1.6,
3.2, 12.5, 25.0 or 50.0 μg/mL). Data are expressed as median, quartiles and extremes
values. Bottom: Phagocytic index. Middle: Proportion of macrophages engaged in
phagocytosis. Top: Average number of S. cerevisiae ingested by macrophage. In the bot-
tom panel, the median of phagocytic index of treated macrophages was higher with 1.6
(p=0.06, Wilcoxon test) and 50 μg/mL (p=0.06, Wilcoxon) than the absence of the
drug. In the middle panel the control was lower than the groups treated with 1.6
(p=0.04, paired t test) or 50.0 μg/mL (p=0.01, paired t test). In the top panel,
1.6 μg/mL of miltefosine increased the number of particles ingested by macrophage
(p=0.03, paired t test).
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spectively, were used. Differences with a two-tailed value of pb0.05
were considered statistically signiﬁcant. The Prism5® software package
(GraphPad, La Jolla, CA, USA, 2005) was employed for statistical tests
and graphical design of the data.3. Results
3.1. Phagocytosis
To assess the effects of different concentrations of miltefosine on
the phagocytosis of yeasts, peritoneal macrophages of C57BL/6 mice
were incubated with S. cerevisiae, previously sensitized or not with
fresh serum of mice, to evaluate the endocytosis through opsonin or
pathogen molecular pattern receptors, respectively.
Our results showed that miltefosine in the concentration of 1.6 and
50.0 μg/mL increased the median of phagocytic capacity of macrophages
Fig. 3. Inﬂuence of treatmentwithmiltefosine on the production of nitric oxide by perito-
nealmacrophages of C57BL/6mice (n=10) infected (top) or not (bottom)with L. amazo-
nensis. Macrophages (2×105)were infected ornotwith Leishmania and co-incubatedwith
miltefosine (0.0, 0.4, 1.6, 3.2, 12.5, 25.0 or 50 μg/mL). Bottom: Miltefosine (50 μg/mL) de-
creased the production of nitrite by the non-infected macrophages (p=0.01, paired t
test). Top: Miltefosine in the concentration of 1.6 μg/mL (p=0.02, paired t test) and
3.2 μg/mL (p=0.0003, paired t test) increased the nitrite production by the infectedmac-
rophages. The data are expressed as median, quartiles and extreme values.
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shown in Fig. 1. Treatment with miltefosine increased the phagocytic
index of macrophages from 49.0 to 78.3 for 1.6 μg/mL and to 105.0 forFig. 4. Inﬂuence of Leishmania infection and miltefosine treatment on the production of
nitrite by peritoneal macrophages of C57BL/6 mice (n=10). Macrophages infected with
L. amazonensis or not, were incubated in the presence or absence of 50 μg/mL of miltefo-
sine in RPMImedium. L. amazonensis increased the production of nitrite (p=0.050, paired
t test), while 50 μg/mL miltefosine decreased NO production (p=0.010, paired t test).
After infection with Leishmania amazonensis treatment of macrophages with 50 μg/mL of
miltefosine increased the production of nitrite (p=0.010, Wilcoxon test). The data are
expressed as median, quartiles and extreme values.50.0 μg/mL (p=0.06, Wilcoxon test) (Fig. 1, bottom); these effects
were a result of the higher the enhancement in the percentage of macro-
phages engaged in phagocytosis both for 1.6 μg/mL (p=0.04, paired t
test) and 50 μg/mL miltefosine (p=0.01, paired t test) (Fig. 1, middle).
To the concentration of 1.6 μg/mLmiltefosine, an increase in the number
of particles ingested by macrophage (p=0.03, paired t test) (Fig. 1, top)
was also observed. The othermiltefosine concentrations (0.4, 3.2, 12.5 or
25.0 μg/mL) did not affect the phagocytic index (p>0.05, Wilcoxon).
When assessed through opsonin receptors, our results showed
that the phagocytic index of macrophages treated with 50 μg/mL of
miltefosine (246.1±34.5) was 208.6% higher than the untreated
macrophages (109.1±60.3) (paired t test, p=0.04) (Fig. 2, bottom);
this result was due to the enhancement in the percentage of macro-
phages engaged in phagocytosis (p=0.001, paired t test) (Fig. 2, mid-
dle), as well as in the number of particles ingested by macrophage
(p=0.05, paired t test) (Fig. 2, top). The other concentrations (0.4,
1.6, 3.2, 12.5 or 25.0 μg/mL) did not affect the phagocytic index
(p>0.05, Wilcoxon test).
3.2. Production of nitric oxide
The production of nitrite by peritoneal macrophages was evaluated
using phagocyte infected or not with L. amazonensis.
The evaluation of nitrite production by non-infected macrophages
showed that 50 μg/mLmiltefosine signiﬁcantly decreased the production
of nitrite from1.1 μMto 0.7 μM(p=0.010,Wilcoxon). The other concen-
trations (0.4, 1.6, 3.2, 12.5, 25.0 or 50.0 μg/mL) did not affect the produc-
tion of nitrite by macrophages (p>0.05, Wilcoxon) (Fig. 3 bottom).
When macrophages were infected with L. amazonensis, the addi-
tion of 1.6 and 3.2 μg/mL miltefosine to the cultures increased the ni-
trite production by macrophages from 1.2 μM to 5.1 (p=0.02, paired
t test) and to 8.8 μM (pb0.001, paired t test) respectively. The other
concentrations of miltefosine did not affect the production of nitrite
by macrophages infected by Leishmania amazonensis (Fig. 3, top).
L. amazonensis infection of macrophages enhanced nitric oxide
production from 1.07 μM to 1.25 μM (p=0.05, paired t test), while
treatment with 50 μg/mL miltefosine decreased NO production to
0.7 μM (p=0.05, paired t test). However, when macrophages were
infected with Leishmania and treated with 50 μg/mL miltefosine,
there was an increase in NO production from 0.7 μM to 1.21 μM
(p=0.01, paired t test) (Fig. 4).
4. Discussion
Our work showed the inﬂuence of different concentrations of milte-
fosine on phagocytic function and nitric oxide production by peritoneal
macrophages of C57BL/6 mice. Miltefosine increased the phagocytic ca-
pacity of macrophages by increasing the number of particles ingested,
either when phagocytosis was assessed using non-sensitized or sensi-
tized S. cerevisiae, suggesting that the drug (1.6 or 50 μg/mL) increased
expression of receptors on the macrophage surface. Furthermore, the
drug also increased the percentage of macrophages engaged in phago-
cytosis, when phagocytosis was assessed using opsonins, suggesting
that miltefosine in the pharmacological concentration of 50 μg/mL
may also have enhanced chemotaxis of macrophages [28,31].
It is possible that miltefosine improved phagocytosis through the
increment in ﬂuidity of the membrane of the macrophage that occurs
by the inhibition of the de novo synthesis of phosphatidylcholine, a
major component of biological membranes [32], consequently im-
proving chemotaxis, motility, adherence of the macrophage and
phagocytosis [20,22,33–38]. Our data agree with the enhanced phago-
cytosis of L. donovani by macrophages of hamsters treated per os with
miltefosine for 5 days [39]. However, differently to our results, Hilgard
et al. [19] showed that miltefosine decreased phagocytosis by macro-
phages of BALB/c mice. It is possible that these differences were caused
by the source of macrophage evaluated, whichwas obtained from bone
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other possibility to explain this different response is the different genet-
ic background of BALB/c and C57BL/6 mice producing different
responses to the same stimuli.
Another possibility to explain the increment in phagocytosis of yeasts
bymiltefosine is some interference of thedrug directly in the composition
of the lipid domains of the membrane. Important features of cellular
membranes are that they can form localized regions with speciﬁc molec-
ular compositions and physical properties, which differ from the average
properties of the rest of membrane. These membrane microdomains,
also known as lipid rafts, are deﬁned by their sphingolipid- and
cholesterol-rich nature, enrichment in GPI-anchored proteins and
membrane-anchored signaling molecules, and cytoskeletal association.
Lipids have a material effect on the phase behavior of these membrane
lipid rafts, which have been shown to function as signal transduction
platforms. Glycosphingolipid-enriched microdomains contain signal
transducers, such as Src family kinases and small G proteins [40], mole-
cules that are involved in phagocytosis [41]. So that, lipid rafts function
as platforms that allow local concentration of rafts-associated proteins,
promoting the interaction of protein complexes, andmodulating signal-
ing. Therefore, treatmentwithmiltefosinemight affect the functionality
of proteins associated to lipid rafts, for instance, receptors and actin
remodeling [40]. In fact, our data showed that miltefosine increased
the number of particles ingested bymacrophage, which suggests an en-
hancement on the expression of receptors, and the proportion of phago-
cytes engaged in phagocytosis, which suggests an enhancement on
chemotaxis, consequently, higher endocytosis of S. cerevisiae, as ob-
served in our results.
We observed that L. amazonensis enhanced and 50 μg/mL miltefosine
inhibited nitric oxide (NO) production by macrophages of C57BL/6 mice,
but whenmacrophages were cocultured with L. amazonensis and 1.6 and
3.2 μg/mLmiltefosine, there was an increase in NO production (Fig.3). In
the presence of Leishmania amazonensis, 50 μg/mL miltefosine also sig-
niﬁcantly enhanced NO production (Fig.4). Wadhone et al. [25] showed
that miltefosine induces iNOS2 in macrophages of BALB/c mice that
peaked around 3–6 h after miltefosine treatment and showed an essen-
tial role of endogenous interferon-γ in restricting the Leishmania load in
macrophages. Furthermore, successful chemotherapy restores the
host's cell-mediated immunity, especially Th1 response. The genetic
background of C57BL/6 already biased to Th1 may explain the different
response observed by us [42]. L. donovani infected-hamsters treated
with the association of miltefosine and paromomycin enhanced the
production of nitrogen metabolites [39]. Furthermore, liposomal milte-
fosine increased NO production by macrophages from BALB/c mice
when in vitro stimulated with LPS [22]. Griewank et al. [15] observed
no inﬂuence on anti-parasite effect of miltefosine against amastigotes
despite the lower capacity of dendritic cells of C57BL/6 mice infected
with L. major to produce NO. The different responses observed in
these studies may reﬂect methodological differences among them and
by different responses due to genetic backgrounds of the different line-
age of mice and Leishmania studied [42].
NO and other reactive oxygen species are molecules involved in
defense against pathogens, and their production depends on infec-
tion, stimulus or drugs. The mechanism by which miltefosine inhibits
NO production observed in this study could be related to the inhibition
of the metabolic pathways by the drug. NO is produced by oxidation of
L-arginine via inducible nitric oxide synthase (iNOS) [43], in the presence
of cytokines, as INF-γ andTNF-α, or LPS [44], as an effect of the enzymatic
activity of protein kinase C (PKC). These ﬁndings could explain the in-
creased NO production by macrophages when they were stimulated
with Leishmania or concomitant stimulated with lower concentration of
miltefosine. Our results showed that miltefosine in the pharmacological
serum concentration inhibited the production of NO by macrophages.
This happened probably due to the inhibitory effect of miltefosine on
the PKC production by a competition with the biological activator phos-
phatidylserine [45,46].Considering that intracellular microorganisms need to be exposed
to microbicidal factors inside lysosomes and oxidative machinery of
the macrophages [44], the improving in the phagocytosis, as an effect
of miltefosine, could favor the elimination of Leishmania or fungus. In
fact, it has been demonstrated that this drug showed anti-Leishmania
[2,4,5,15] and anti-fungus properties [7–10].
Besides its anti-parasitic effect, nitric oxide also plays a critical role in
tissue damage through its interaction with oxygen-derived radicals,
generating highly toxic effectors molecules, such as peroxynitrites
[47]. Oncemiltefosine inhibits the production of NO, production of per-
oxynitrite should also be inhibited, which could reduce tissue damage
caused by infectious diseases. So that, it should also be considered that
the inhibition of excessive production of NO by miltefosine, as observed
in thiswork, could favor the better evolution of infectious diseases, byde-
creasing the immunopathogenetic process.
In conclusion,we demonstrated that miltefosine enhanced phagocy-
tosis by macrophages, both when it was assessed without or with opso-
nins. Miltefosine also inhibited NO production by macrophages, but it
increased NO production when the macrophages were concomitantly
incubated with the L. amazonensis and the drug. As these functions of
phagocytes are the main innate immune defense against microorgan-
isms, miltefosine, beyond its microbicidal effects, may favor the better
evolution of the disease by improvingmacrophage functions, and in ad-
dition, by decreasing the immunopathogenesis of the diseases.
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